AVDL
Avadel PharmaceuticalsAVDL
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.
Employees: 154
0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
96% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 24
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
14% more funds holding
Funds holding: 153 [Q2] → 175 (+22) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]
0.25% less ownership
Funds ownership: 77.71% [Q2] → 77.45% (-0.25%) [Q3]
27% less call options, than puts
Call options by funds: $35.8M | Put options by funds: $48.9M
29% less capital invested
Capital invested by funds: $1.37B [Q2] → $978M (-$393M) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$13
65%
upside
Avg. target
$16.75
112%
upside
High target
$21
166%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma 55% 1-year accuracy 12 / 22 met price target | 77%upside $14 | Buy Maintained | 13 Jan 2025 |
Piper Sandler David Amsellem 60% 1-year accuracy 24 / 40 met price target | 65%upside $13 | Overweight Maintained | 10 Jan 2025 |
HC Wainwright & Co. Oren Livnat 50% 1-year accuracy 23 / 46 met price target | 166%upside $21 | Buy Reiterated | 10 Jan 2025 |
Needham Ami Fadia 50% 1-year accuracy 82 / 165 met price target | 141%upside $19 | Buy Maintained | 9 Jan 2025 |
Financial journalist opinion
Based on 6 articles about AVDL published over the past 30 days
Positive
MarketBeat
1 week ago
There May Still Be Time to Get in on These 3 Trending Biotechs
Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
Positive
Seeking Alpha
2 weeks ago
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Negative
Seeking Alpha
2 weeks ago
Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook
Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz was significantly below expectations due to increasing patient attrition. The company is increasing efforts to address some of these challenges and to increase uptake among patients switching from other oxybates. Last year's legal updates have significantly reduced the risk of ruin, with Lumryz staying on the market for narcolepsy, but there was also the loss on the idiopathic hypersomnia side.
Neutral
GlobeNewsWire
3 weeks ago
Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch
-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients on LUMRYZ as of December 31, 2024, including 600 patients that initiated therapy in the fourth quarter --
Neutral
GlobeNewsWire
3 weeks ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to twelve (12) new employees to purchase an aggregate of 131,700 ordinary shares under Avadel's 2021 Inducement Plan. The awards were granted as an inducement material to the employee's acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee's respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel's 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.
Neutral
GlobeNewsWire
4 weeks ago
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Neutral
GlobeNewsWire
2 months ago
Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET.
Neutral
Seeking Alpha
2 months ago
Avadel Pharmaceuticals plc (AVDL) Q3 2024 Earnings Call Transcript
Avadel Pharmaceuticals plc (NASDAQ:AVDL ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Austin Murtagh - Director, Precision AQ Greg Divis - CEO Richard Kim - CCO Jennifer Gudeman - SVP, Medical & Clinical Affairs Tom McHugh - CFO Conference Call Participants Andrew Tsai - Jefferies François Brisebois - Oppenheimer Oren Livnat - H.C. Wainwright Ami Fadia - Needham David Amsellem - Piper Sandler Operator Good day everyone and welcome to today's Avadel Pharmaceuticals 3Q 2024 Earnings Call.
Neutral
GlobeNewsWire
3 months ago
Avadel Pharmaceuticals Announces Favorable Ruling in Administrative Procedure Act Litigation
DUBLIN, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that yesterday, the U.S. District Court for the District of Columbia (“Court”) ruled in favor of the Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) under the Administrative Procedure Act regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in adults with narcolepsy. With this ruling, the approval of LUMRYZ is upheld based on the FDA's determination that LUMRYZ is clinically superior to Jazz's twice-nightly oxybate products.
Positive
Zacks Investment Research
3 months ago
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
Charts implemented using Lightweight Charts™